Table 2

Description of lipid lowering use and treatment needed to obtain LDL-c goals in statin naïve patients and statin users

Statin naïve patients
n=150
p Value
1° prev vs 2° prev
Statin users
n=47
p Value
1° prev vs 2° prev
Statin naïve vs statin users in 1° prev/2° prev p value
1° prev
n=29
2° prev
n=121
1° prev
n=13
2° prev
n=34
Type of statin n (%)
 Rosuvastatin0 (0.0)90 (74.4)<0.0011 (7.7)5 (14.7)0.520.13/<0.001
 Atorvastatin23 (79.3)27 (22.3)<0.0018 (61.5)22 (64.7)0.840.23/<0.001
 Simvastatin6 (20.7)4 (3.3)0.0013 (23.1)7 (20.6)0.850.86/0.001
 Pravastatin1 (7.7)0 (0.0)0.100.13/–
Dosage n (%)
 Intensive1 (3.4)90 (74.4)<0.001 1 (7.7)19 (55.9)0.0030.55/0.04
 Moderate26 (89.7)28 (23.1)<0.001 10 (76.9)15 (44.1)0.040.28/0.02
 Low2 (.9)3 (2.5)0.23 2 (15.4)0 (0.0)0.020.39/0.35
Need for change of statin medication n (%)3 (10.3)8 (6.8)0.515 (38.5)23 (67.6)0.070.03/<0.001
Number of statin changes mean±SD0.10±0.310.12±0.390.880.71±0.490.81±0.540.680.02/<0.001
Number of statin dose adjustments mean±SD0.28±0.530.25±0.700.841.29±1.251.32±0.700.920.002/<0.001
  • LDL-c, low density lipoprotein cholesterol; prev, prevention.